Nail and periungual toxicity following capecitabine therapy.
作者信息
Vaccaro Mario, Barbuzza Olga, Guarneri Fabrizio, Guarneri Biagio
出版信息
Br J Clin Pharmacol. 2008 Aug;66(2):325-6. doi: 10.1111/j.1365-2125.2008.03174.x. Epub 2008 Apr 1.
Abstract
摘要
相似文献
1
Nail and periungual toxicity following capecitabine therapy.
Br J Clin Pharmacol. 2008 Aug;66(2):325-6. doi: 10.1111/j.1365-2125.2008.03174.x. Epub 2008 Apr 1.
2
Longitudinal melanonychia induced by capecitabine.
Dermatol Online J. 2009 Oct 15;15(10):11.
3
Capecitabine induced colitis.
Pathol Res Pract. 2014 Sep;210(9):606-8. doi: 10.1016/j.prp.2014.05.005. Epub 2014 May 22.
4
Onycholysis with the appearance of a "sunset" secondary to capecitabine.
Cutis. 2003 Sep;72(3):234-6.
5
[Onycholysis with hyponychium exudate secondary to chemotherapy with paclitaxel and capecitabine].
Actas Dermosifiliogr. 2006 Oct;97(8):536-8. doi: 10.1016/s0001-7310(06)73459-7.
6
Capecitabine-induced subacute cutaneous lupus erythematosus: report of a case with positive rechallenge test.
J Dermatol. 2013 Nov;40(11):939-40. doi: 10.1111/1346-8138.12281. Epub 2013 Sep 23.
7
Dermatomyositis associated with capecitabine in the setting of malignancy.
J Am Acad Dermatol. 2014 Feb;70(2):e47-8. doi: 10.1016/j.jaad.2013.10.025.
8
Nail changes during docetaxel containing combination chemotherapy.
Korean J Intern Med. 2004 Jun;19(2):132-3. doi: 10.3904/kjim.2004.19.2.132.
9
Capecitabine in gastric cancer.
Drugs Today (Barc). 2008 Aug;44(8):629-40. doi: 10.1358/dot.2008.44.8.1244748.
10
Occurrence of subacute cutaneous lupus erythematosus after treatment with fluorouracil and capecitabine.
J Am Acad Dermatol. 2008 Aug;59(2 Suppl 1):S4-6. doi: 10.1016/j.jaad.2007.06.040.
引用本文的文献
1
Onychomadesis associated with chemotherapy: case report and mini literature review.
Drug Des Devel Ther. 2017 Aug 14;11:2373-2376. doi: 10.2147/DDDT.S139643. eCollection 2017.
2
Compound mucocutaneous adverse effects of oral capecitabine in a patient.
Indian Dermatol Online J. 2014 Jul;5(3):349-52. doi: 10.4103/2229-5178.137804.
本文引用的文献
1
Capecitabine (Xeloda) as monotherapy in advanced breast and colorectal cancer: effectiveness and side-effects.
Anticancer Res. 2007 May-Jun;27(3B):1653-6.
2
Drug reactions affecting the nail unit: diagnosis and management.
Dermatol Clin. 2007 Apr;25(2):215-21, vii. doi: 10.1016/j.det.2007.01.006.
3
Nail toxicity associated with epidermal growth factor receptor inhibitor therapy.
J Am Acad Dermatol. 2007 Mar;56(3):460-5. doi: 10.1016/j.jaad.2006.09.013. Epub 2006 Dec 4.
4
Capecitabine: a review.
Clin Ther. 2005 Jan;27(1):23-44. doi: 10.1016/j.clinthera.2005.01.005.
5
Onycholysis with the appearance of a "sunset" secondary to capecitabine.
Cutis. 2003 Sep;72(3):234-6.
6
Exudative hyponychial dermatitis associated with capecitabine and docetaxel combination chemotherapy for metastatic breast carcinoma: report of three cases.
Br J Dermatol. 2003 May;148(5):1071-3. doi: 10.1046/j.1365-2133.2003.05272.x.
7
Taxane-induced nail changes: incidence, clinical presentation and outcome.
Ann Oncol. 2003 Feb;14(2):333-7. doi: 10.1093/annonc/mdg050.
8
Pyogenic granuloma-like lesions during capecitabine therapy.
Br J Dermatol. 2002 Dec;147(6):1270-2. doi: 10.1046/j.1365-2133.2002.05000_6.x.
9
Onychomadesis and onycholysis associated with capecitabine.
Br J Dermatol. 2001 Sep;145(3):521-2. doi: 10.1046/j.1365-2133.2001.04391.x.
10
A method for estimating the probability of adverse drug reactions.
Clin Pharmacol Ther. 1981 Aug;30(2):239-45. doi: 10.1038/clpt.1981.154.
Zotero 插件